TUESDAY, July 10, 2018 -- The "low-T" craze appears to be waning, with fewer men in the United States turning to testosterone therapy as a way to stave off aging and sexual decline.
A steep decrease in testosterone prescriptions occurred between 2013 and 2016, coinciding with public warnings that hormone therapy could increase men's risk of heart health issues and prostate cancer.
WEDNESDAY, June 27, 2018 -- Men with localized high-risk prostate cancer can slow its spread by using a cancer drug that's already on the market, a new clinical trial shows.
The targeted drug enzalutamide (Xtandi) reduced by 71 percent these men's risk of either dying from their prostate cancer or having the cancer spread to other organs, compared against a placebo. The drug also delayed their prostate cancer's reappearance by nearly two years, the researchers said.